These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 17257497)
1. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange. Geng SS; Feng J; Li Y; Sun Y; Gu X; Huang Y; Wang Y; Kang X; Chang H; Shen B Cell Mol Immunol; 2006 Dec; 3(6):439-43. PubMed ID: 17257497 [TBL] [Abstract][Full Text] [Related]
2. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies. Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806 [TBL] [Abstract][Full Text] [Related]
3. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. Shan D; Press OW; Tsu TT; Hayden MS; Ledbetter JA J Immunol; 1999 Jun; 162(11):6589-95. PubMed ID: 10352275 [TBL] [Abstract][Full Text] [Related]
4. [Expression and Characterization of Single-chain Fv-Fc Fusion Protein against Human P185(erbB2)]. Xie ZG; Guo N; Shi M; Feng JN; Yu M; Sun YX; Shen BF Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):371-4. PubMed ID: 12673393 [TBL] [Abstract][Full Text] [Related]
5. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548 [TBL] [Abstract][Full Text] [Related]
6. The design, construction and function of a new chimeric anti-CD20 antibody. Wang Y; Feng J; Huang Y; Gu X; Sun Y; Li Y; Shen B J Biotechnol; 2007 May; 129(4):726-31. PubMed ID: 17433484 [TBL] [Abstract][Full Text] [Related]
7. Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells. Cao M; Cao P; Yan H; Lu W; Ren F; Hu Y; Zhang S Appl Biochem Biotechnol; 2009 Jun; 157(3):562-74. PubMed ID: 19099209 [TBL] [Abstract][Full Text] [Related]
8. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935 [TBL] [Abstract][Full Text] [Related]
9. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019 [TBL] [Abstract][Full Text] [Related]
10. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer]. Wang Y; Li X; Chen W Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168 [TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen. Bose B; Khanna N; Acharya SK; Sinha S J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690 [TBL] [Abstract][Full Text] [Related]
12. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Conner J; Braidwood L; Brown SM Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918 [TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034 [TBL] [Abstract][Full Text] [Related]
14. Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1. Adamson PJ; Millard DJ; Hohmann AW; Mavrangelos C; Macardle PJ; Pilkington G; Mulhern TD; Tedder TF; Zola H; Nicholson IC Mol Immunol; 2006 Feb; 43(6):550-8. PubMed ID: 15936081 [TBL] [Abstract][Full Text] [Related]
15. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348 [TBL] [Abstract][Full Text] [Related]
16. [Expression of ATR-Fc fusion protein in CHO cells]. Gao LH; Hu XW; Chen W; Xu JJ; Zhao J; Chen HP Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):826-31. PubMed ID: 16285529 [TBL] [Abstract][Full Text] [Related]